Patents Examined by Catherine Hibbert
  • Patent number: 8759503
    Abstract: Isolated nucleic acid sequence encoding the CD20 gene comprising SEQ ID NO: 5, recombinant vector comprising a nucleic acid sequence placed under the control of one or a plurality of elements required for the expression thereof in a host cell, and method for improving the efficacy of a treatment comprising using a nucleic acid sequence comprising SEQ ID NO: 5.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: June 24, 2014
    Assignee: Etablissement Francais du Sang
    Inventors: Christophe Ferrand, Marina Deschamps, Carole Henry, Pierre Tiberghien, Christophe Borg, Pierre-Simon Rohrlich
  • Patent number: 8758990
    Abstract: The present invention relates to compositions and methods for detecting Mycobacterium genus (Mycobacterium sp.) bacteria (e.g., M. tuberculosis) and M. avium complex (MAC; M. avium, M. scrofulaceum and M. intracellulaire) in a clinical sample or culture. The present invention also relates to differentiating cultures or samples comprising (Mycobacterium sp.) bacteria (e.g., M. tuberculosis) from cultures or samples comprising M. avium complex (MAC; M. avium, M. scrofulaceum and M. intracellulaire).
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: June 24, 2014
    Assignee: ID-Fish Technology, Inc.
    Inventors: Jyotsna S. Shah, Helena Weltman
  • Patent number: 8741638
    Abstract: Methods for the maximizing parameter of the in vitro growth and expansion of mammalian cells, specifically postpartum-derived cells in containers such as roller bottles is described. Methods of optimizing growth rate and cell yield in such culture systems are provided. The methods are particularly adapted for human postpartum-derived cells, such as umbilicus-derived cells.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: June 3, 2014
    Assignee: DePuy Synthes Products, LLC
    Inventor: Alexander M. Harmon
  • Patent number: 8735341
    Abstract: A conjugate comprises: (a) a mitochondrial membrane-permeant peptide; (b) an active agent or compound of interest such as a detectable group or mitochondrial protein or peptide; and (c) a mitochondrial targeting sequence linking said mitochondrial membrane-permeant peptide and said active mitochondrial protein or peptide. The targeting sequence is one which is cleaved within the mitochondrial matrix, and not cleaved within the cellular cytoplasm, of a target cell into which said compound is delivered. Methods of use of such compounds are also described.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: May 27, 2014
    Assignee: Wake Forest University
    Inventor: R. Mark Payne
  • Patent number: 8722637
    Abstract: Methods and compositions relating to IG20 expression, splice variants of IG20, effects of endogenous DENN-SV function with respect to processes regulating cell proliferation, cell survival and cell death are disclosed.
    Type: Grant
    Filed: September 22, 2004
    Date of Patent: May 13, 2014
    Assignee: The Board of Trustees of the University of Illinois
    Inventor: Bellur S. Prabhakar
  • Patent number: 8715959
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a Group H nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Grant
    Filed: February 20, 2002
    Date of Patent: May 6, 2014
    Assignee: Intrexon Corporation
    Inventors: Subba Reddy Palli, Mohan Basavaraju Kumar, Dean Ervin Cress, Ted Tsutomu Fujimoto
  • Patent number: 8715928
    Abstract: A gene profiling signature for diagnosis and prognosis of cancer patients is disclosed herein. In one embodiment, the gene signature includes 32 or 79 cancer survival factor-associated genes. Thus, provided herein is a method of determining the prognosis of a subject with a tumor by detecting expression of five of more cancer survival factor-associated genes in a tumor sample and comparing expression of the five or more cancer survival factor-associated genes in the tumor sample to a control. In some examples, an increase in expression of ABCF1, CORO1C, DPP3, PREB, UBE3A, and PTDSS1 in a tumor sample compared to a control sample indicates poor prognosis. Also provided is a method of treating a patient diagnosed with cancer by administering a therapeutically effective amount of an agent that alters expression or activity of one or more of the disclosed cancer survival factor-associated genes.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: May 6, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Steven K. Libutti, Mei He
  • Patent number: 8691506
    Abstract: The present invention relates to a method for providing a gene expression profile being predictive for the specific response of an individual tumor to a pharmaceutically effective compound, the use thereof, a microarray wherein the nucleotide sequences attached to the substrate consist of nucleotide sequences corresponding to the predictive genes of said gene expression profile, and a diagnostic kit containing said microarray.
    Type: Grant
    Filed: April 13, 2006
    Date of Patent: April 8, 2014
    Assignee: Oncotest GmbH
    Inventors: Niko Bausch, Heinz-Herbert Fiebig, André Korrat, Martina Maurer, Thomas Metz, Julia Schüler
  • Patent number: 8648183
    Abstract: It is intended to provide base sequences participating in the regulation of the expression of a promoter. It is also intended to modify a promoter based on the base sequence data to give a modified promoter having a high expression activity. Namely, a modified promoter constructed by inserting a first DNA fragment containing CCAATNNNNNN (SEQ ID NO:1) (a first base sequence) and a second DNA fragment containing CGGNNNNNNNNNGG (SEQ ID NO:2) (a second base sequence) into a promoter functioning in a filamentous fungus, wherein N in the base sequence denotes A (adenine), G (guanine), C(cytosine), or T (thymine).
    Type: Grant
    Filed: February 28, 2003
    Date of Patent: February 11, 2014
    Assignee: Amano Enzyme Inc.
    Inventors: Kanako Suzuki, Norihiro Tsukagoshi
  • Patent number: 8637237
    Abstract: Ecdysteroid action in Drosophila melanogaster and other insects is mediated by the dimerization of two nuclear receptors, the ecdysone receptor (EcR) and Ultraspiracle (USP), which regulate the transcription of target genes. Disclosed are nucleic acid constructs to identify insecticides having the ability to modify insect development and growth in a developmental stage-specific and/or species-specific manner.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: January 28, 2014
    Assignee: The University of North Carolina at Greensboro
    Inventors: Vincent C. Henrich, Cary Alan Weinberger
  • Patent number: 8632963
    Abstract: The present invention provides a method for allowing foreign particles to penetrate, very efficiently, the cell wall, cell membrane, organelle membrane and/or nuclear membrane of a cell and hybridizing or binding to the complimentary target in the cell. The cells may be from a culture or from specimens obtained from a patient. The foreign particle can be a probe consisting of, for example, either individually or in any combination of two or more of the following: DNA, RNA, peptide nucleic acids (PNA), glycopeptides, lipopeptides, glycolipids or prions. The target is a cell, a cell component or, preferably, a pathogen or pathogen component. The pathogen can be, for example, bacteria, fungi, yeast or viruses.
    Type: Grant
    Filed: July 27, 2006
    Date of Patent: January 21, 2014
    Assignee: ID-FISH Technology Inc.
    Inventors: Jyotsna Shah, Helena Weltman
  • Patent number: 8623909
    Abstract: Disclosed is a method for screening a compound having an activity that selectively modulates an androgen receptor, comprising a step of measuring the mRNA expression level of prostate-specific antigen or the production level of prostate-specific antigen in prostate cancer cells by contacting a test substance with the prostate cancer cells, and a step of measuring the mRNA expression level of uncoupling protein 1 or the production level of uncoupling protein 1 in adipocytes by contacting a test substance with the adipocytes. Additionally disclosed is a selective androgen receptor modulator, comprising as an active ingredient thereof a compound represented by any of structural formulas (I) to (III), and a composition for preventing or treating a lifestyle-related disease, comprising as an active ingredient thereof said selective androgen receptor modulator.
    Type: Grant
    Filed: May 8, 2009
    Date of Patent: January 7, 2014
    Assignees: Aska Pharmaceutical Co., Ltd.
    Inventors: Hajime Nawata, Toshihiko Yanase, Takayoshi Nakagawa
  • Patent number: 8617535
    Abstract: The present invention provides cytotherapeutic units comprising predetermined numbers of selected types of potent cells. Assurance of the nature and identities of such cells is achieved through assay and certification of said numbers and identities. Therapeutic modalities are provided. Libraries of cell preparations with assayed and preferably certified populations are preferred and the preparation of cell preparations tailored to specific patients or disease states are provided.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: December 31, 2013
    Assignee: Anthrogenesis Corporation
    Inventor: Robert J. Hariri
  • Patent number: 8614059
    Abstract: A method of simultaneously co-purifying and concentrating nucleic acid and protein targets into a single volume is described. The method includes automation of the entire sample preparation process, performed by having an analyst add a sample into a device that performs all of the steps necessary to prepare a sample for analysis. The method provides for samples are not split during the sample preparation process and where common purification methods can be used for purifying multiple analytes.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: December 24, 2013
    Assignee: The Johns Hopkins University
    Inventor: Charles C. Young
  • Patent number: 8609328
    Abstract: The present invention provides a pancreatic islet isolation method comprising the steps of (1) injecting a protection solution containing a protease inhibitor into the pancreatic duct of an procured pancreas; (3) digesting the pancreas into which the protection solution has been injected; and (4) purifying the digested pancreatic tissue using a purification solution containing a density gradient reagent. The present invention also provides a protection solution for injection into the pancreatic duct, a pancreas preservation solution for the two-layer method, and an islet purification solution.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: December 17, 2013
    Assignee: Otsuka Pharmaceutical Factory, Inc.
    Inventors: Shinichi Matsumoto, Hiromi Wada, Hirofumi Noguchi
  • Patent number: 8535908
    Abstract: Expression vectors for expression of a protein or polypeptide of interest as a fusion product composed of the protein or polypeptide of interest fused at one terminus to a solubility enhancing peptide extension are provided. Sequences encoding the peptide extensions are provided. The invention further comprises antibodies which bind specifically to one or more of the solubility enhancing peptide extensions.
    Type: Grant
    Filed: January 8, 2010
    Date of Patent: September 17, 2013
    Assignee: Brookhaven Science Associates, LLC
    Inventors: Paul I. Freimuth, Yian-Biao Zhang, Jason Howitt
  • Patent number: 8476040
    Abstract: The present invention generally relates to methods and compositions for expressing proteins or polypeptides in prokaryotic hosts using eukaryotic signal sequences.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: July 2, 2013
    Assignee: Xoma Technology Ltd.
    Inventors: Jeff Gray, Joe Buechler, Uday Kumar Veeramallu
  • Patent number: 8461320
    Abstract: The subject invention lies in the field of microorganism mutation and selection of the mutants. In particular, the invention is directed at obtaining metabolic mutants in a simple, direct and specific manner. In a preferred embodiment it is also possible to obtain desired mutants not comprising recombinant DNA, thereby facilitating incorporation thereof in products for human consumption or application, due to shorter legislative procedures. The method according to the invention involves random mutation and specific selection of the desired metabolic mutant. Knockout, mutants wherein a gene associated with metabolism is absent or inactivated and mutants with increased or decreased DNA binding capacity are also claimed.
    Type: Grant
    Filed: April 22, 2003
    Date of Patent: June 11, 2013
    Assignee: DuPont Nutrition Biosciences ApS
    Inventors: Leendert Hendrik De Graaff, Henriëtta Catharina Van Den Broeck, Jacob Visser
  • Patent number: 8389207
    Abstract: Disclosed herein are methods for identifying agents capable of affecting the expression, posttranslational modification, and/or an activity of TRB3, for example, in adipose tissue and/or adipocytes. Such agents are useful, for example, to mobilize fat stores and as prospective obesity therapeutics.
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: March 5, 2013
    Assignee: Salk Institute for Biological Studies
    Inventors: Marc Montminy, Jose E. Heredia, Ling Qi
  • Patent number: 8389236
    Abstract: The invention relates to a translational recoding reporter construct comprising: a first fluorescent protein coding sequence; a second fluorescent protein coding sequence encoding a fluorescent protein different from the first fluorescent protein; and a linker sequence interposed between the first and second fluorescent protein coding sequence; wherein the first fluorescent protein coding sequence and the second fluorescent protein coding sequence are out-of-frame with respect to each other but are co-expressed as a single fusion polypeptide upon recoding. The invention also relates to methods of use of the construct in screening modulators of recoding.
    Type: Grant
    Filed: August 30, 2006
    Date of Patent: March 5, 2013
    Assignee: Otago Innovation Limited
    Inventors: Tony Stuart Cardno, Warren Perry Tate